Tag : OPTIMA TRIAL

CONFERENCE UPDATE

OPTIMA trial: Multigene expression assay safely guides chemotherapy decisions in high-risk ER+/HER2- eBC
The phase 3 OPTIMA trial demonstrated that Prosigna-guided test-directed therapy achieved noninferior invasive breast cancer-free survival (IBCFS) vs. standard chemo-endocrine therapy in high-clinical-risk ER+/HER2-negative early breast cancer (eBC), supporting the use of multigene expression assays to inform individualized adjuvant chemotherapy decisions.